Get the Stockscreener App
1.88
1.57%
-0.03
After Hours:
1.89
0.01
+0.53%
Annexon Inc stock is traded at $1.88, with a volume of 863.74K.
It is down -1.57% in the last 24 hours and down -23.89% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$1.91
Open:
$1.89
24h Volume:
863.74K
Relative Volume:
0.52
Market Cap:
$184.32M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-1.0621
EPS:
-1.77
Net Cash Flow:
$-121.34M
1W Performance:
+28.77%
1M Performance:
-23.89%
6M Performance:
-74.59%
1Y Performance:
-59.04%
1-Day Range:
$1.80
$1.90
1-Week Range:
$1.40
$1.96
52-Week Range:
$1.285
$7.85
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650)-822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
1.88 | 184.32M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Investors in cash trouble should check out Annexon Inc (ANNX) - Sete News
SEC Form DEFA14A filed by Annexon Inc. - Quantisnow
JP Morgan analysts upgrades an Overweight rating for Annexon Inc (ANNX) - knoxdaily.com
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Geode Capital Management LLC - Defense World
ANNX’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com
Annexon Inc (ANNX) Stock: A Year of Market Fluctuations - investchronicle.com
Alliancebernstein L.P. Reduces Stock Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Sees Large Decrease in Short Interest - Defense World
JPMorgan Chase & Co. Has $7.75 Million Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | ANNX Stock News - GuruFocus
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Annexon Strengthens Team with Strategic Equity Package: Inside the $1.54 Share Grant - Stock Titan
Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck (NASDAQ:ANNX) - Seeking Alpha
Vanguard Group Inc. Buys 576,625 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
KLP Kapitalforvaltning AS Takes $98,000 Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
American Century Companies Inc. Has $916,000 Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder - AOL.com
Why Annexon Inc. (ANNX) Went Down On Thursday? - Yahoo Finance
Annexon Touts ‘Rapid’ and ‘Durable’ Improvements for Targeted Guillain-Barré Therapy - BioSpace
Annexon Highlights Pivotal Data on First Potential Targeted Ther - GuruFocus
Annexon Cites 'Durable Benefit' of Tanruprubart in Guillain-Barre Syndrome Trial - MarketScreener
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting - The Manila Times
Annexon Highlights Pivotal Data on First Potential Targeted - GlobeNewswire
First-Ever Targeted GBS Therapy Achieves Remarkable Recovery Rates in Landmark Trial - Stock Titan
Prudential Financial Inc. Boosts Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon stock hits 52-week low at $1.73 amid sharp annual decline - Investing.com
Annexon Highlights Leadership in Advancing Clinical - GlobeNewswire
First-Ever Targeted GBS Treatment: Annexon's Phase 3 Data Could Change Patient Care - Stock Titan
Teacher Retirement System of Texas Makes New $106,000 Investment in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Inc (ANNX) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Here's Why We're Not Too Worried About Annexon's (NASDAQ:ANNX) Cash Burn Situation - Yahoo Finance
135,000 Shares in Annexon, Inc. (NASDAQ:ANNX) Purchased by Swiss National Bank - Defense World
Annexon Inc (NASDAQ: ANNX) Slashes -7.49%: The Most Likely Path Going Forward - Stocks Register
Annexon, Inc. (NASDAQ:ANNX) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Annexon stock hits 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa
Annexon stock hits 52-week low at $2.28 amid market challenges - Investing.com Australia
Bank of New York Mellon Corp Acquires 6,226 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Inc (NASDAQ: ANNX): Down -60.53% In 2025, Outlook Remains Negative - Stocks Register
Annexon Inc (ANNX) With A Potential Upside Of More Than -460.0% - Stocks Register
Quarterly Metrics: Quick and Current Ratios for Annexon Inc (ANNX) - The Dwinnex
Annexon (ANNX) Projected to Post Earnings on Tuesday - Defense World
Annexon Strengthens Team with 35,000-Share Stock Option Grant to Key New Hire - StockTitan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
19,895 Shares in Annexon, Inc. (NASDAQ:ANNX) Acquired by Arizona State Retirement System - Defense World
Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks - markets.businessinsider.com
Annexon: Despite Major Catalysts, Stock Is Trading Almost At Cash (NASDAQ:ANNX) - Seeking Alpha
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of “Buy” by Analysts - Defense World
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely - simplywall.st
Rhumbline Advisers Purchases 5,854 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Q1 Earnings Forecast for Annexon Issued By HC Wainwright - Defense World
Annexon Biosciences: Promising Developments and Strategic Milestones Justify Buy Rating - TipRanks
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):